Nephron Research LLC

Here we go! Today, The 2024 Nephron Research Pharmacy & PBM Innovation Symposium is underway and centering on challenges to traditional Pharmacy and PBM business practices with a specific focus on new reimbursement models (i.e.: cost+), new direct-to-consumer pharmacy models (i.e.: LillyDirect), new PBM technologies (i.e.: modern platforms and consumer experiences) and new regulatory and legal threats (i.e.: FTC, legislation and ERISA lawsuits). https://lnkd.in/ehBw8qrJ Blue Shield of California Capital Rx Eli Lilly and Company Walgreens Boots Alliance Prime Therapeutics Eric Percher Sasha Simpson Paul Heldman

Nephron’s Health Policy Team reviewed #Medicare drug spending and other data to predict in a May 22nd research note the next 15 brand-name drugs that will most likely be subject Medicare drug price negotiation/setting under the #InflationReductionAct. https://lnkd.in/e49MXwxb Paul HeldmanSasha SimpsonJayne Chung

Excited to announce 2024 Nephron Research Pharmacy & PBM Innovation Symposium - this year with a focus on challenges to traditional Pharmacy and PBM business practices. #pbm #pharmacybenefit #pharmacybenefitmanager Walgreens Boots Alliance Eli Lilly and Company Blue Shield of California Prescryptive Health, Inc. Capital Rx Rightway Eric Percher Paul Heldman Sasha Simpson

To kick off our recently-completed NephronNEXT Private Growth Conference, our coverage teams took a moment to walk attendees through their view of the "State of the Market" for each subsector. MedTech analyst Chris Pasquale also discussed how Nephron's unique model enables us to add value to our clients' processes. That entails not only developing a deep understanding of the factors influencing the healthcare markets today, but also seeing around corners to predict the sector's evolution and what models and technologies will have the most impact going forward. Getting to know private companies is an intrinsic part of that process. The highly curated group of innovators and disruptors presenting at NephronNEXT represent, quite simply, the themes, models, and technologies which will define the future of healthcare investing. https://lnkd.in/gUKa9_Yf

Nephron’s Health Policy team held a call this week with FDA expert Jeff Gibbs on the outlook for an upcoming final LDT rule. Jeff provided insightful and timely commentary on prospects for labs seeking grandfathering status, the potential for academic medical centers gaining a carve out, and how to think about the impact of a potential lawsuit and upcoming November elections. https://lnkd.in/erC-i4k5 Labcorp Quest Diagnostics #LDTRegulation #NIPT #pharmacogenetics #hospitals #FDA

NephronNEXT Private Growth Conference is April 10th! Check out the full roster of healthcare innovators and disruptors presenting below. https://lnkd.in/eWNEf-ez Aledade, Inc.Alto PharmacyBeta BionicsBetterHealthBillionToOneCarbon HealthConcertAIDeepcellGeneoscopyJenaValve Technology, Inc.Komodo HealthNuvaira, Inc.Pearl HealthSetPoint MedicalTruepillUltima GenomicsVertos MedicalViz.aiVolta Labs, Inc.Vytalize Health

On April 10th, join us at NephronNEXT, a series of virtual presentations and meetings with a curated set of private company innovators and disruptors designed to help investors discover what’s NEXT in healthcare. For more information: https://lnkd.in/eWNEf-ez Ultima Genomics Carbon Health SetPoint Medical Nuvaira, Inc. Vertos Medical Geneoscopy JenaValve Technology, Inc. Komodo Health Beta Bionics BillionToOne Aledade, Inc. Truepill Better Health Group Volta Labs, Inc. Alto Pharmacy Monogram Health

Love is in the air today at Nephron. Chris Pasquale is out with his annual "matchmaker" note and joined this year by Joshua Raskin and Eric Percher who got just a little jealous. Together they published thoughts on a total of ten hypothetical combinations across the #medtech and #healthcareservices sectors. https://lnkd.in/eAKtXxUN

Nephron Research is hiring! https://lnkd.in/ePqmsZNp

Happy to share a further expansion of the Nephron Research LLC bench. Welcome Tom!